Switzerland-based Novartis Venture Funds is seeking investment targets in Taiwan to invest US$15 million and US$20 million per company in the biotechnology sector, the firm said yesterday.
Novartis Venture Funds is an arm of pharmaceutical company Novartis International AG. It has already invested biotechnology companies in China and South Korea.
“Five local companies recommended by the Institute for Biotechnology and Medicine Industry briefed us this morning,” Margaret Chang, senior manager of drug maker Novartis Taiwan Co, said on Tuesday on the sideline of 2013 International Biomedical Venture Forum.
Chang declined to give the names of the firms, but said that two made cancer drugs, one was a diagnostic medical device provider, one produced medical equipment and the other was a research institute.
“We are looking for biomedical firms that can leverage the highly developed information technology industry in Taiwan,” said Reinhard Ambros, global head of the venture firm.
Before making any investment, Ambros said the company would have to form a research team to look at potential targets, or find local partners.
“We need people who have local knowledge and can speak the local language,” he said.
The US$800 million Novartis Venture Funds makes an average of five to eight new investments a year, Ambros said.
Meanwhile, John Hsuan (宣明智), vice chairman emeritus of United Microelectronics Corp (UMC, 聯電), the world’s No. 3 contract chipmaker, indicated that he was interested in investing in Taiwan’s biotechnology sector.
“The biomedical industry in Taiwan is of great potential, but we still lack a flagship company,” Hsuan said, adding that he could contribute to the growth of local biotechnology firms by injecting capital.
Hsuan said he has initiated an angel fund to make such investments. The fund has attracted 70 members, besides himself, each of whom can invest at least NT$50,000. He declined to reveal the size of the fund.
However, he said the fund has invested in five local companies, three of which are biotechnology firms.
However, Lu Hong-bo (盧洪波), executive director of US-based private equity and venture capital firm OrbiMed Advisors LLC’s Asia branch, was more cautious about investing in the Taiwanese biotech sector.
“The valuation of Taiwanese biomedical companies is higher than their peers in Hong Kong and the US, making us wonder whether there is a biotechnology bubble here,” Lu said. “There seems to be too much money chasing too few targets in Taiwan.”
Lu said she expects there will be corrections for share prices of local biotechnology companies, but in the long term such firms will still be growing.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts